Approved Use

KYPROLIS® (carfilzomib) is a prescription medication used to treat adult patients with relapsed or refractory multiple myeloma who have received one to three previous treatments for multiple myeloma... Read More

Are you a healthcare professional?

The information provided in this section is intended expressly for healthcare professionals in the United States. Click “Yes, I am” to enter if you are a U.S. healthcare professional.

img img
Step 5
Believe in yourself

I have a great support system that I feel so blessed to have. I love my nurse at my center, who I can call and know that she’ll get back to me as soon as possible. My husband and my mom are my rocks.

KYPROLIS® Patient Support

It can be challenging to start a new treatment regimen when multiple myeloma relapses. The KYPROLIS® Patient Support program can help you feel more in control and confident about taking the next step.

The Patient Support program is designed to provide you with important information about KYPROLIS®, including educational materials that can help support you through your treatment journey. The program provides tools and services for patients, caregivers, and other members of your support circle.

Sign up here

The support you need is never far. KYPROLIS® support programs are here for you, your caregivers, and anyone interested in learning more

AMGEN Nurse Navigators*

Sometimes you need someone who knows what you’re going through. That’s why Amgen offers patients who are prescribed KYPROLIS® the Amgen Assist 360™ and Nurse Navigator program. Your Amgen Nurse Navigator will be your single point of contact for Amgen Assist 360™ services and will help you find the program resources most important to you.

Sign up here

An AMGEN Nurse Navigator can help you with:

Finding the resources most
important to you

Amgen Nurse Navigators* can refer you to independent nonprofit organizations that may provide community resources, one-on-one counseling services, and local support groups.

Understanding
your coverage

Learn how KYPROLIS® may be covered and find programs that may make treatment more affordable, such as Amgen FIRST STEP™.

Answering your
medication questions

Work with our Amgen Nurse Navigators* to answer questions concerning your Amgen medication.

* Amgen Nurse Navigators are there to support, not replace, your treatment plan and do not provide medical advice, nursing, or case management services. Patients should always consult their healthcare provider regarding medical decisions or treatment concerns.

Resources include referrals to independent nonprofit patient assistance programs. Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofits' criteria. Amgen has no control over these programs and provides referrals as a courtesy only.

Financial assistance for KYPROLIS®

Knowing your options is a powerful thing. Amgen is committed to ensuring patients have access to KYPROLIS®.

If you are eligible
and commercially insured

The Amgen FIRST STEP™ program can help you cover your out-of-pocket prescription costs, including deductible, co-insurance, and co-payment.

  • $0 out-of-pocket for first dose or cycle
  • $5 out-of-pocket for subsequent doses or cycles, up to the brand program benefit maximum
  • No income eligibility requirement

If you are on government
insurance (like Medicare)

Amgen Nurse Navigators* can refer you to independent nonprofit patient assistance programs that may be able to help you afford KYPROLIS® co-pay costs.

If you are uninsured
or underinsured

The Amgen Safety Net Foundation is a nonprofit patient assistance program sponsored by Amgen that helps qualifying patients access Amgen medicines at no cost.

*Amgen Nurse Navigators are there to support, not replace, your treatment plan and do not provide medical advice, nursing, or case management services. Patients should always consult their healthcare provider regarding medical decisions or treatment concerns.

Resources include referrals to independent nonprofit patient assistance programs. Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofits' criteria. Amgen has no control over these programs and provides referrals as a courtesy only.

Subject to program eligibility requirements and coverage limits. See AmgenFIRSTSTEP.com for details. This program is not open to patients receiving prescription reimbursement under any federal, state, or government-funded healthcare program, such as Medicare, Medicare Advantage, Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), the Department of Defense (DoD) or TRICARE®, or where otherwise prohibited by law.

For Karl, [re]remission was possible with KYPROLIS®

Hear his story

Individual results may vary.

Additional resources

These downloadable tools provide further information about KYPROLIS® as well as ways to help you stay organized over the course of treatment.

KYPROLIS® patient brochure

Get helpful information about how KYPROLIS® may help you live longer

Weekly treatment tracker for KYPROLIS® + Rd (Revlimid® + dexamethasone)

Help keep track of treatment and appointments

Weekly treatment tracker for KYPROLIS® + DARZALEX® (daratumumab) + dexamethasone

Help keep track of treatment and appointments

Weekly treatment tracker for KYPROLIS® + d (dexamethasone)

Help keep track of treatment and appointments

Weekly treatment tracker for KYPROLIS® + DARZALEX® (daratumumab) + dexamethasone

Help keep track of treatment and appointments

Weekly treatment tracker for KYPROLIS® + Rd (Revlimid® + dexamethasone)

Help keep track of treatment and appointments

Lab results tracker

Keep track of M-protein and other lab numbers

Have questions about KYPROLIS®?
Find answers to frequently asked questions

IMPORTANT SAFETY INFORMATION

KYPROLIS® (carfilzomib) can cause serious side effects:

  • Heart problems: KYPROLIS can cause heart problems or worsen pre-existing heart conditions. Death due to cardiac arrest has occurred within one day of KYPROLIS administration. Before starting KYPROLIS, you should have a full medical work-up (including blood pressure and fluid management). You should be closely monitored during treatment.
  • Kidney problems: There have been reports of sudden kidney failure in patients receiving KYPROLIS. Your kidney function should be closely monitored during treatment.
  • Tumor lysis syndrome (TLS): Cases of TLS have been reported in patients receiving KYPROLIS, including fatalities. You should be closely monitored during treatment for any signs of TLS.
  • Lung damage: Cases of lung damage have been reported in patients receiving KYPROLIS, including fatal cases.
  • Pulmonary hypertension (high blood pressure in the lungs): There have been reports of pulmonary hypertension in patients receiving KYPROLIS.
  • Lung complications: Shortness of breath was reported in patients receiving KYPROLIS. Your lung function should be closely monitored during treatment.
  • High blood pressure: Cases of high blood pressure, including fatal cases, have been reported in patients receiving KYPROLIS. Your blood pressure should be closely monitored during treatment.
  • Blood clots: There have been reports of blood clots in patients receiving KYPROLIS. If you are at high risk for blood clots, your doctor can recommend ways to lower the risk.
  • If you are using KYPROLIS in combination with dexamethasone or with lenalidomide plus dexamethasone or with daratumumab and dexamethasone, your doctor should assess and may prescribe another medicine to help lower your risk for blood clots.
  • If you are using birth control pills or other medical forms of birth control associated with a risk of blood clots, talk to your doctor and consider a different method of birth control during treatment with KYPROLIS in combination with dexamethasone, with lenalidomide plus dexamethasone, or with daratumumab and dexamethasone.
  • Infusion-related reactions: Signs and symptoms of infusion-related reactions included fever, chills, joint pain, muscle pain, facial flushing and/or swelling, swelling of the larynx (voice box), vomiting, weakness, shortness of breath, low blood pressure, fainting, chest tightness, and chest pain. These symptoms can occur immediately following infusion or up to 24 hours after administration of KYPROLIS. If you experience any of these symptoms, contact your doctor immediately.
  • Severe bleeding problems: Fatal or serious cases of bleeding problems have been reported in patients receiving KYPROLIS. Your doctor should monitor your signs and symptoms of blood loss.
  • Very low platelet count: Low platelet levels can cause unusual bruising and bleeding. You should have regular blood tests to check your platelet count during treatment.
  • Liver problems: Cases of liver failure, including fatal cases, have been reported in patients receiving KYPROLIS. Your liver function should be closely monitored during treatment.
  • Blood problems: Cases of a blood disease called thrombotic microangiopathy, including thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), including fatal cases, have been reported in patients who received KYPROLIS. Your doctor should monitor your signs and symptoms.
  • Brain problems: A nerve disease called Posterior Reversible Encephalopathy Syndrome (PRES), formerly called Reversible Posterior Leukoencephalopathy Syndrome (RPLS), has been reported in patients receiving KYPROLIS. It can cause seizure, headache, lack of energy, confusion, blindness, altered consciousness, and other visual and nerve disturbances, along with high blood pressure. Your doctor should monitor your signs and symptoms.
  • Cases of a brain infection called Progressive Multifocal Leukoencephalopathy (PML), including fatal cases, have been reported in patients receiving KYPROLIS. Your doctor should monitor your signs and symptoms.
  • KYPROLIS should not be combined with melphalan and prednisone: Newly diagnosed transplant ineligible multiple myeloma patients have shown an increased risk of serious and fatal side effects when using KYPROLIS in combination with melphalan and prednisone.
  • Possible fetal harm: KYPROLIS can cause harm to a fetus (unborn baby) when given to a pregnant woman. Women should use effective contraception during treatment with KYPROLIS and for 6 months following the final dose. Men should use effective contraception during treatment with KYPROLIS and for 3 months following the final dose. KYPROLIS can cause harm to a fetus if used during pregnancy or if you or your partner become pregnant during treatment with KYPROLIS.
You should contact your doctor immediately if you experience any of the following:
  • Shortness of breath
  • Prolonged, unusual or excessive bleeding
  • Yellowing of the skin and/or eyes (jaundice)
  • Headaches, confusion, seizures, or loss of sight
  • Pregnancy (women should not receive KYPROLIS if they are pregnant or breastfeeding)
  • Any other side effect that bothers you or does not go away
What are the possible side effects of KYPROLIS?
  • The most common side effects occurring in at least 20% of patients receiving KYPROLIS in the combination therapy trials are: low red blood cell count, diarrhea, tiredness (fatigue), high blood pressure (hypertension), fever, upper airway (respiratory tract) infection, low platelets, cough, difficulty breathing and sleeplessness (insomnia).

These are not all the possible side effects of KYPROLIS. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‑800‑FDA‑1088. 1‑800‑FDA‑1088.

Please see full Product Information.

APPROVED USE

  • KYPROLIS® (carfilzomib) is a prescription medication used to treat adult patients with relapsed or refractory multiple myeloma who have received one to three previous treatments for multiple myeloma. KYPROLIS is approved for use in combination with daratumumab plus dexamethasone, dexamethasone or with lenalidomide plus dexamethasone, which are other medicines used to treat multiple myeloma.